COA
TEVA icon

Charter Oak Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

Charter Oak Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-430,300
Closed -$9.48M – 17
2024
Q4 		$9.48M Buy
+430,300
New +$7.83M 5.43% 8

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

Charter Oak Advisors's TEVA Position: Q1 2025 in Review

Charter Oak Advisors sold out of Teva Pharmaceuticals (TEVA) in Q1 2025, closing a stake of 430,300 shares — an estimated $9.48M sold.

Charter Oak Advisors first reported a position in TEVA in Q4 2024 and held it in 1 quarter. The position peaked at $9.48M in Q4 2024. 560 funds tracked by Wall St. Rank hold TEVA as of Q1 2025.

  • Charter Oak Advisors reported no remaining Teva Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Charter Oak Advisors sold 430,300 Teva Pharmaceuticals shares in Q1 2025, an estimated $9.48M.
  • Charter Oak Advisors first reported a position in Teva Pharmaceuticals in Q4 2024 and held it in 1 quarter.
  • Charter Oak Advisors's Teva Pharmaceuticals position peaked at $9.48M in Q4 2024.
  • 560 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2025.

Based on Charter Oak Advisors's 13F filing for Q1 2025, filed 13 May 2025.